<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03928990</url>
  </required_header>
  <id_info>
    <org_study_id>P/2018/376</org_study_id>
    <nct_id>NCT03928990</nct_id>
  </id_info>
  <brief_title>Assesment of Physical Activity Level of Patients With Multiple Sclerosis: From Laboratory to Real Life</brief_title>
  <acronym>ACTISEP</acronym>
  <official_title>Assesment of Physical Activity Level of Patients With Multiple Sclerosis: From Laboratory to Real Life</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to assess the feasibility of a protocol determining individual
      moderate-to-vigorous physical activity (MVPA) thresholds, among multiple sclerosis patients,
      in routine medical practice.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 15, 2019</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient's feeling</measure>
    <time_frame>Day 1</time_frame>
    <description>Patient's feeling measured at each step of the procedure, measured with Visual Analogique Scale (scored from 0 = not painful to 10 = extremely painful)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Experimental arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ActiGraph accelerometer</intervention_name>
    <description>ActiGraph accelerometer + calibration with Cortex MetaMax3B ergospirometer</description>
    <arm_group_label>Experimental arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 18 to 80 years old

          -  Multiple sclerosis according to McDonald criteria ;

          -  Expanded Disability Status Scale (EDSS) between 0 and 6.5 ;

          -  Patient able to move with or without mechanical assistance.

        Exclusion Criteria:

          -  Deterioration of neurological symptomatology within 60 day before enrollment ;

          -  Changes brought to the multiple sclerosis treatment within 6 months before enrollment
             ;

          -  Introduction of a treatment acting on spasticity or fatigue within 30 day before
             enrollment

          -  Changes brought to reeducation protocol throughout the duration of the study

          -  Patient unable to provide an effort equivalent to 3 times the resting metabolic value
             = 3 Metabolic Equivalent of Task (METs).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yoshimasa Sagawa Jr., PhD</last_name>
    <phone>00333 81 21 87 51</phone>
    <email>ysagawajunior@chu-besancon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Besançon</name>
      <address>
        <city>Besançon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yoshimasa Sagawa, PhD</last_name>
      <phone>0033 3 81 21 87 51</phone>
      <email>ysagawajunior@chu-besancon.fr</email>
    </contact>
    <investigator>
      <last_name>Thierry Moulin, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre Decavel, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 24, 2019</study_first_submitted>
  <study_first_submitted_qc>April 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2019</study_first_posted>
  <last_update_submitted>April 24, 2019</last_update_submitted>
  <last_update_submitted_qc>April 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

